Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
-15.00 (-0.31%)
Real-time:   3:36PM GMT+1
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,833.00 - 4,879.00
52 week 2,707.19 - 5,180.00
Open 4,840.00
Vol / Avg. 786,048.00/1.68M
Mkt cap 43.64B*
P/E 30.18
Div/yield 3.51*
EPS 1.60*
Shares 898.56M
Beta     -
Inst. own     -
Nov 10, 2016
Shire PLC Investor Day - 1:30PM GMT - Add to calendar
Oct 28, 2016
Q3 2016 Shire PLC Earnings Release Add to calendar
Sep 7, 2016
Shire PLC at Wells Fargo Securities Healthcare Conference Add to calendar
Aug 2, 2016
Q2 2016 Shire PLC Earnings Call
Aug 2, 2016
Q2 2016 Shire PLC Earnings Release
Jun 9, 2016
Shire PLC at Jefferies Healthcare Conference
Jun 8, 2016
Shire PLC at Goldman Sachs Global Healthcare Conference

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 3.60% 20.88%
Operating margin 3.96% 22.12%
EBITD margin - 44.15%
Return on average assets 0.74% 8.86%
Return on average equity 1.73% 14.47%
Employees 5,548 -
CDP Score - 91 B


5 Riverwalk Citywest Business Campus, Dublin 24
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Ginger Gregory Chief Human Resource Officer
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 52
Phil J. Vickers Head of Research and Development
Age: 55
Oliver Strawbridge Senior Assistant Company Secretary
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 57
Olivier Bohuon Non-Executive Director
Age: 56
Gail D. Fosler Non-Executive Director
Age: 68
Sara Mathew Non-Executive Director
Age: 60